Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chun-Ming Hong

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Journal of Hepatology|December 15, 2024
All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver diseaseShang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, et al.
American Journal of Cancer Research|July 10, 2023
High PIVKA-II level and ASAP score predict 1-year risk of hepatocellular carcinoma in non-cirrhotic chronic hepatitis B patientsYi-Cheng Lu, Tung-Hung Su, Tai-Chung Tseng, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus InfectionChen-Hua Liu, Yih-Sharng Chen, Sheoi-Shen Wang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 5, 2023
Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapyMeng-Ju Lin, Tung-Hung Su, Chun-Jen Liu, et al.
The American Journal of Gastroenterology|June 26, 2024
Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis BShang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 29, 2024
Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapyKai-Chun Chang, Tung-Hung Su, Sih-Han Liao, et al.
European Journal of Heart Failure|January 8, 2025
Metabolic dysfunction-associated steatotic liver disease is associated with increased risks of heart failureKai-Chun Chang, Tung-Hung Su, Cho-Kai Wu, et al.
JHEP Reports : Innovation in Hepatology|December 13, 2023
HBcrAg-based risk score performs better than the HBV DNA-based scores for HCC prediction in grey zone patients who are HBeAg-negativeTai-Chung Tseng, Tetsuya Hosaka, Chun-Jen Liu, et al.
Cancer|September 6, 2024
Outcomes of radiofrequency ablation for hepatocellular carcinoma with concurrent steatotic liver diseaseFeng-Pai Tsai, Tung-Hung Su, Shang-Chin Huang, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 8, 2023
Serial increase and high alpha-fetoprotein levels predict the development of hepatocellular carcinoma in 6 monthsTung-Hung Su, Shan-Han Chang, Chi-Ling Chen, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Journal of Hepatology|December 15, 2024
All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver diseaseShang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, et al.
American Journal of Cancer Research|July 10, 2023
High PIVKA-II level and ASAP score predict 1-year risk of hepatocellular carcinoma in non-cirrhotic chronic hepatitis B patientsYi-Cheng Lu, Tung-Hung Su, Tai-Chung Tseng, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus InfectionChen-Hua Liu, Yih-Sharng Chen, Sheoi-Shen Wang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 5, 2023
Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapyMeng-Ju Lin, Tung-Hung Su, Chun-Jen Liu, et al.
The American Journal of Gastroenterology|June 26, 2024
Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis BShang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 29, 2024
Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapyKai-Chun Chang, Tung-Hung Su, Sih-Han Liao, et al.
European Journal of Heart Failure|January 8, 2025
Metabolic dysfunction-associated steatotic liver disease is associated with increased risks of heart failureKai-Chun Chang, Tung-Hung Su, Cho-Kai Wu, et al.
JHEP Reports : Innovation in Hepatology|December 13, 2023
HBcrAg-based risk score performs better than the HBV DNA-based scores for HCC prediction in grey zone patients who are HBeAg-negativeTai-Chung Tseng, Tetsuya Hosaka, Chun-Jen Liu, et al.
Cancer|September 6, 2024
Outcomes of radiofrequency ablation for hepatocellular carcinoma with concurrent steatotic liver diseaseFeng-Pai Tsai, Tung-Hung Su, Shang-Chin Huang, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 8, 2023
Serial increase and high alpha-fetoprotein levels predict the development of hepatocellular carcinoma in 6 monthsTung-Hung Su, Shan-Han Chang, Chi-Ling Chen, et al.
Pageof 4